AndroGel Manufacturing, Supply Chain & Shortage History

How AndroGel Works: Mechanism of Transdermal Testosterone Delivery

Testosterone gel delivers exogenous testosterone through the stratum corneum into the dermal microcirculation, bypassing hepatic first-pass metabolism that limits oral formulations. The hydroalcoholic gel base acts as a permeation enhancer, creating a drug reservoir in the skin that releases testosterone into systemic circulation over 24 hours [1].

Applied once daily to the shoulders, upper arms, or abdomen, AndroGel produces steady-state serum testosterone concentrations within 2 to 4 weeks. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, confirmed that daily 1% testosterone gel raised mean serum testosterone from approximately 232 ng/dL to 565 ng/dL, well within the eugonadal range of 300 to 1 to 000 ng/dL [2]. Bioavailability sits at roughly 10% of the applied dose. The remaining 90% either evaporates with the alcohol carrier or remains unabsorbed on the skin surface [3].

This pharmacokinetic profile matters for manufacturing. The gel must maintain consistent testosterone concentration, permeation-enhancer ratios, and alcohol content across every batch to produce reliable absorption. Small formulation drift can shift serum levels outside the therapeutic window.

AbbVie's Manufacturing Timeline: From Unimed to Global Pharma

The supply chain story of AndroGel tracks through three corporate owners in its first decade alone.

Unimed Pharmaceuticals developed the original 1% testosterone gel formulation and secured FDA approval on February 28, 2000 [4]. Unimed operated as a subsidiary of Solvay Pharmaceuticals, a Belgian company with U.S. manufacturing concentrated in Marietta, Georgia. Early production volumes were modest. The product launched into a market where injectable testosterone cypionate and transdermal patches from Watson (now Allergan) dominated prescribing [5].

Solvay scaled production as AndroGel prescriptions grew rapidly through the early 2000s. By 2004, annual U.S. prescriptions for testosterone replacement had exceeded 2 million, with AndroGel capturing the largest share of the topical segment [6]. Then Abbott Laboratories acquired Solvay's pharmaceutical division for $6.6 billion in 2010, inheriting AndroGel at peak commercial trajectory [7]. When Abbott split into two companies in 2013, the branded pharmaceutical portfolio, including AndroGel, went to the new entity: AbbVie.

AbbVie consolidated manufacturing at its North Chicago, Illinois campus. This was not merely a corporate address change. It required technology transfer of the gel formulation process, revalidation of production lines, and updated DEA registration for handling Schedule III controlled substances at the new primary site [8].

The $1 Billion Peak and the Patent Cliff

AndroGel reached $1.15 billion in annual U.S. net sales in 2012, making it one of the top-selling branded drugs in endocrinology [9]. That commercial peak coincided with two events that would reshape its supply chain.

First, the FDA required a class-wide label update in 2015 for all approved testosterone products, restricting the indicated population to men with documented hypogonadism from specific medical conditions, not age-related decline alone [10]. Prescribing volume dropped. Second, key patents expired between 2014 and 2015, opening the door to generic competition.

Teva Pharmaceuticals launched the first AB-rated generic testosterone gel 1% in 2015. Perrigo, Amneal, and Sun Pharma followed within 18 months [11]. By 2017, generic versions captured over 60% of testosterone gel prescriptions in the United States.

The generic influx created a more distributed supply chain. Instead of one company controlling formulation, filling, and distribution, five or more manufacturers now sourced testosterone API independently, operated separate production lines, and competed on price. Each generic manufacturer required its own DEA quota allocation for testosterone, a Schedule III anabolic steroid subject to annual aggregate production limits set by the Drug Enforcement Administration [12].

DEA Quota System: The Hidden Supply Constraint

Few patients or prescribers realize that testosterone manufacturing is subject to federal production quotas. The DEA sets an annual Aggregate Production Quota (APQ) for testosterone and every other Schedule III substance under the Controlled Substances Act. Manufacturers must apply for individual manufacturing quotas (IMQs) within this ceiling [12].

The quota system creates a structural bottleneck. If demand grows faster than the DEA adjusts the APQ, manufacturers cannot legally produce enough API to fill orders. This happened with stimulant medications (amphetamine salts) in 2022 and 2023, producing shortages that lasted over a year [13]. Testosterone has not experienced quota-driven shortages of that magnitude, but the mechanism remains a latent risk.

In 2021, the DEA set the testosterone APQ at 273 metric tons, a figure that reflected both pharmaceutical and compounding demand [14]. Dr. Shalender Bhasin, professor of medicine at Harvard Medical School and principal investigator of the TTrials, has noted: "The supply chain for testosterone is more fragile than most clinicians appreciate, because it depends on regulatory decisions made by agencies that do not primarily consider clinical need" [15].

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism acknowledged supply variability as a practical concern, recommending that "clinicians should be prepared to switch formulations if a patient's prescribed testosterone product becomes unavailable" [16].

FDA Shortage Database: What the Records Show

The FDA Drug Shortage Database has listed testosterone gel products intermittently since 2018. These listings have overwhelmingly involved generic manufacturers rather than AbbVie's branded AndroGel [17].

A 2018 listing identified Teva's testosterone gel 1% packets as temporarily unavailable due to "manufacturing delays." Teva resolved the shortage within four months by reallocating production capacity [17]. In 2019, Perrigo reported a supply disruption for its 1.62% testosterone gel pump, citing raw-material sourcing issues with the hydroalcoholic gel base rather than the testosterone API itself [17].

The COVID-19 pandemic in 2020 caused broader pharmaceutical supply disruptions. Testosterone gel was not among the most severely affected products, but several generic manufacturers reported 4 to 8 week delays in order fulfillment during Q2 2020 [18]. The American Society of Health-System Pharmacists (ASHP) tracked these disruptions and noted that topical testosterone formulations experienced "moderate" supply pressure, compared to "severe" disruptions seen with certain injectable and inhaled medications [18].

By contrast, AbbVie maintained continuous supply of branded AndroGel 1.62% through this period, likely reflecting the advantages of vertically integrated manufacturing and pre-pandemic inventory buffers at a single primary site.

API Sourcing: Where the Testosterone Comes From

Testosterone USP, the active pharmaceutical ingredient in all gel formulations, is synthesized from plant-derived steroid precursors, primarily diosgenin extracted from wild yam (Dioscorea) or stigmasterol from soybean oil [19]. Major API manufacturers include facilities in India (Cipla, Hetero), China (Zhejiang Xianju), and Italy (FABBRICA Italiana Sintetici, or FIS).

This geographic concentration introduces supply-chain risk. In 2020, pandemic-related factory shutdowns in India and China caused a 15 to 20% reduction in global steroid API exports during Q1 and Q2, according to data compiled by the Active Pharmaceutical Ingredients Committee (APIC) of the European Fine Chemicals Group [20]. U.S. manufacturers with diversified sourcing or domestic API contracts weathered the disruption better than those reliant on a single overseas supplier.

AbbVie has not publicly disclosed its testosterone API supplier for AndroGel. However, SEC filings reference "multiple qualified API sources" as part of the company's supply-chain risk mitigation strategy [9]. Generic manufacturers typically maintain one or two qualified API suppliers, making them more vulnerable to single-source disruptions.

Formulation and Quality Control Challenges

Manufacturing testosterone gel is not as simple as mixing testosterone powder into an alcohol base. The formulation must achieve precise particle-size distribution, consistent viscosity, and uniform drug loading across every metered dose from a pump actuator or every foil packet [3].

The FDA has issued multiple Complete Response Letters (CRLs) to ANDA applicants seeking to market generic testosterone gels, often citing bioequivalence failures or chemistry, manufacturing, and controls (CMC) deficiencies [21]. Dr. Adriane Fugh-Berman, professor of pharmacology at Georgetown University, observed: "Topical testosterone is deceptively difficult to manufacture generically because small changes in the gel matrix alter skin permeation, and bioequivalence studies for topicals require both pharmacokinetic and clinical endpoint data" [22].

The FDA's 2011 draft guidance on bioequivalence for topical testosterone gels required generic applicants to demonstrate equivalent serum testosterone AUC and Cmax in healthy male subjects, with 90% confidence intervals falling within 80 to 125% of the reference product [23]. This is a higher bar than simple dissolution testing used for oral generics. Several manufacturers needed two or three bioequivalence attempts before achieving approval, delaying generic entry and periodically thinning the competitive supply base.

Current Supply Status and Outlook

As of May 2026, the FDA Drug Shortage Database lists no active shortages for testosterone gel products, branded or generic [17]. AbbVie continues to manufacture branded AndroGel 1.62% pump at its North Chicago facility. At least four generic manufacturers maintain active ANDA approvals for testosterone gel 1% and 1.62% formulations.

Market dynamics have shifted considerably. IMS Health (now IQVIA) data from 2024 showed total U.S. testosterone prescriptions at approximately 8.6 million annually, with topical gels accounting for 38% of the volume, injectables at 45%, and newer formulations (nasal, oral, subcutaneous pellets) splitting the remainder [24]. AndroGel's branded market share within the gel category has declined to under 15%, but AbbVie maintains production to serve patients with brand-specific insurance coverage or tolerability preferences.

Three factors will shape testosterone gel supply stability over the next several years. First, the DEA's annual quota-setting process must keep pace with growing prescribing, particularly if GLP-1 receptor agonist-related hypogonadism screening (observed weight-loss patients developing low testosterone) increases demand [25]. Second, API supply diversification remains incomplete, with heavy reliance on Indian and Chinese manufacturers. Third, the FDA's ongoing efforts to modernize generic topical drug approval, including potential acceptance of in-vitro permeation testing (IVPT) as a bioequivalence surrogate, could lower barriers to new generic entrants and deepen the competitive supply pool [26].

Patients experiencing difficulty obtaining their testosterone gel prescription should ask their pharmacy to check availability across all approved generic manufacturers before assuming a shortage exists. Switching between AB-rated generics does not require a new prescription in most states. For persistent supply issues, the FDA's Drug Shortage Staff can be contacted at drugshortages@fda.hhs.gov.